改良安卡拉痘苗病毒疫苗接种可提供针对鼻内兔痘病毒攻击的长期保护。
Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.
作者信息
Jones Dorothy I, McGee Charles E, Sample Christopher J, Sempowski Gregory D, Pickup David J, Staats Herman F
机构信息
Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
出版信息
Clin Vaccine Immunol. 2016 Jul 5;23(7):648-51. doi: 10.1128/CVI.00216-16. Print 2016 Jul.
Abstract
Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.
摘要
改良安卡拉痘苗病毒（MVA）是一种天花疫苗候选物。本研究旨在确定接种MVA是否能提供针对兔痘病毒（RPXV）攻击的长期保护，兔痘病毒是天花的一种动物模型。接种两剂MVA可对接种9个月后经鼻内给予的致死性RPXV攻击提供100%的保护。
相似文献
1
Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.
Clin Vaccine Immunol. 2016 Jul 5;23(7):648-51. doi: 10.1128/CVI.00216-16. Print 2016 Jul.
2
Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Virology. 2005 Sep 1;339(2):164-75. doi: 10.1016/j.virol.2005.06.002.
3
Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Vaccine. 2007 Jan 2;25(1):34-42. doi: 10.1016/j.vaccine.2006.07.022. Epub 2006 Aug 1.
4
Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
J Virol. 2004 Nov;78(22):12471-9. doi: 10.1128/JVI.78.22.12471-12479.2004.
5
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.
Vaccine. 2009 Sep 4;27(40):5496-504. doi: 10.1016/j.vaccine.2009.06.105. Epub 2009 Jul 24.
6
E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
Viruses. 2018 Jan 4;10(1):21. doi: 10.3390/v10010021.
7
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Vaccine. 2007 Feb 9;25(8):1513-25. doi: 10.1016/j.vaccine.2006.10.047. Epub 2006 Nov 7.
8
Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
J Infect Dis. 2009 Jan 1;199(1):39-48. doi: 10.1086/595565.
9
Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
J Virol. 2005 Jun;79(12):7845-51. doi: 10.1128/JVI.79.12.7845-7851.2005.
10
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10889-94. doi: 10.1073/pnas.0804985105. Epub 2008 Aug 4.
引用本文的文献
1
Are We Prepared in Case of a Possible Smallpox-Like Disease Emergence?
Viruses. 2017 Aug 27;9(9):242. doi: 10.3390/v9090242.
2
40 Years without Smallpox.
Acta Naturae. 2017 Oct-Dec;9(4):4-12.
3
Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
Adv Virus Res. 2017;97:187-243. doi: 10.1016/bs.aivir.2016.07.001. Epub 2016 Aug 1.
本文引用的文献
1
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Lancet Infect Dis. 2014 Dec;14(12):1196-207. doi: 10.1016/S1473-3099(14)70963-6. Epub 2014 Oct 30.
2
Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.
PLoS One. 2012;7(11):e48706. doi: 10.1371/journal.pone.0048706. Epub 2012 Nov 2.
3
Licensure of vaccines using the Animal Rule.
Curr Opin Virol. 2012 Jun;2(3):353-6. doi: 10.1016/j.coviro.2012.01.004. Epub 2012 Jan 30.
4
Developmental and reproductive toxicity testing of vaccines.
J Pharmacol Toxicol Methods. 2012 Mar;65(2):58-63. doi: 10.1016/j.vascn.2011.12.001. Epub 2011 Dec 30.
5
Stable dry powder formulation for nasal delivery of anthrax vaccine.
J Pharm Sci. 2012 Jan;101(1):31-47. doi: 10.1002/jps.22742. Epub 2011 Sep 8.
6
Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.
PLoS One. 2011 Jan 27;6(1):e16532. doi: 10.1371/journal.pone.0016532.
7
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.
8
Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus.
PLoS One. 2010 Sep 20;5(9):e12880. doi: 10.1371/journal.pone.0012880.
9
Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.
Vaccine. 2010 Oct 4;28(42):6901-14. doi: 10.1016/j.vaccine.2010.08.006. Epub 2010 Aug 17.
10
Animal models of orthopoxvirus infection.
Vet Pathol. 2010 Sep;47(5):852-70. doi: 10.1177/0300985810378649. Epub 2010 Aug 3.
Zotero 插件